Condition: Psychosis Associated With Alzheimer's Disease · Sponsor: Intra-Cellular Therapies, Inc.
This is a multicenter, randomized, double-blind, parallel-group, placebo-controlled, flexible-dose study evaluating the efficacy, safety, and tolerability of ITI-1284 compared with placebo in the treatment of psychosis in patients with AD.
This description comes directly from the study's public registry record.
Study Contact · 844-434-4210 · Participate-In-This-Study1@its.jnj.com
Always discuss trial participation with your own doctor first.
| Advanced Research Center, Inc | Anaheim, California, United States | Recruiting |
| Pharmacology Research Institute | Los Alamitos, California, United States | Terminated |
| Wr Pri Llc | Newport Beach, California, United States | Completed |
| ATP Clinical Research | Orange, California, United States | Suspended |
| Sunwise Clinical Research | Walnut Creek, California, United States | Recruiting |
| Envision Trials LLC | Bonita Springs, Florida, United States | Recruiting |
| Clinical Research of Brandon | Brandon, Florida, United States | Suspended |
| Healthcare Innovations Institute Inc | Coral Springs, Florida, United States | Completed |
| Brain Matters Research | Delray Beach, Florida, United States | Completed |
| Science Connections LLC | Doral, Florida, United States | Recruiting |
| Homestead Associates in Research Inc | Homestead, Florida, United States | Suspended |
| K2 Medical Research | Maitland, Florida, United States | Recruiting |
+ 53 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06540833